Study design
T2DM
Patients were randomly allocated to either the omega-3 group, managed by glimepiride 3 mg tablets plus omega 3 capsules [1000 mg fish oil, 13% of eicosapentaenoic acid (EPA) and 9% docosahexaenoic acid (DHA)] daily, or the control group, managed by glimepiride 3 mg plus placebo daily for 12 weeks, in a controlled, single-blind parallel clinical study. Placebo capsules contained corn oil, linoleic acid and were identical in shade and taste with omega 3 fish oil capsules produced by the Arab Company for Gelatin and Pharmaceutical products, El-Amreya, Alexandria, Egypt. Participants had to be willing to participate, be 30–60 years old, had T2DM for at least 2 years, have HbA1C score of more than 7% [